The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
about
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsAcid-base and electrolyte disorders associated with the use of antidiabetic drugs.Implications of the EMPA-REG Trial for Clinical Care and Research.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Effect of diuretics on renal tubular transport of calcium and magnesium.Review article: effects of type 2 diabetes therapies on bone metabolism.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Complex interplay among adiposity, insulin resistance and bone health.The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.
P2860
Q33567077-DDFE48C6-00DB-49B2-8FC7-64E36DAED6BCQ38658251-B0C9CE7A-B2F6-468A-8225-A384CEA872E5Q38798623-8CDA9480-089D-467B-BC6C-80BE5B53728BQ38842559-92839186-8B25-4A3C-891E-729766A1A676Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590DQ39000587-A683990F-6106-4B2C-A90C-858B1B22E94EQ39003573-6FA6894E-9CFC-4603-9065-0857C5756F3AQ39022309-0A375F09-B4D5-4A29-85E4-B9A94EC5AC07Q39039079-8AC38545-AD3A-41DE-92F3-6CB69BF2B155Q39169297-83227C07-53EA-4815-8ACD-5A4D6215EB2CQ42363966-4496CE86-CFC7-41EE-899E-724974E35C02Q47700645-128BB33B-0AC9-449A-8834-F3497B2EB643Q50044972-A5086B36-4DD0-44FC-A737-DC46E6310EEEQ53757094-090DD5C7-34C7-468B-999C-86B3F93FC82EQ55411384-288C2196-0B91-4D81-8B32-2AEC0EB637C6
P2860
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
type
label
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
prefLabel
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
P2093
P2860
P1476
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
P2093
Albert Fung
Maria Alba
Mehul Desai
P2860
P304
P356
10.1080/03007995.2016.1174841
P407
P577
2016-04-05T00:00:00Z